Clinical Report: Integration of Genetic and Proteomic Data Reveals Predictive Plasma Biomarkers for Multiple Sclerosis
Overview
This study identifies 39 plasma proteins causally implicated in multiple sclerosis (MS) using an integrated genetic-proteomic approach.
Background
Multiple sclerosis (MS) remains an incurable disease despite advancements in therapies targeting its inflammatory component. Early intervention is crucial, as the disease process may begin years before clinical symptoms appear.
Data Highlights
The study utilized 2,545 protein measurements from 3 cohorts, totaling 80,824 individuals, to derive genetically predicted protein levels and assess their association with MS in an independent set of 14,802 cases and 26,703 controls.
Key Findings
39 causal proteins associated with MS risk were nominated through an integrated genetic-proteomic approach.
DKKL1 was identified as a candidate protein with protective effects on both MS risk and severity.
The integrated approach improved fine-mapping resolution by more than 10-fold, identifying novel MS risk loci.
Validation of predictive value for the identified proteins was conducted in individuals diagnosed with MS up to 15 years prior.
Discordance across proteomic platforms was resolved in this study.
Clinical Implications
The identification of plasma proteins associated with MS risk may facilitate further research into their roles in the disease.
Conclusion
The integration of genetic and proteomic data presents a method for identifying biomarkers in multiple sclerosis.
